Alyssa Agarwal

Alyssa Agarwal

Auto-generated profile, based on publicly available information

Alyssa Agarwal

Department of Epidemiology of Microbial Diseases, Yale School of Public Health

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2022 in Science Advances
Verified
Journal Article
Open access
HCHeather M. Callaway
Heather M. Callaway
DZDawid S Zyla
Dawid S Zyla
FLFlorence Larrous
Florence Larrous
GMGuilherme Dias de Melo
Guilherme Dias de Melo
KHKathryn M. Hastie
Kathryn M. Hastie
ESErica Ollmann Saphire
Erica Ollmann Saphire
Rabies infection is nearly 100% lethal if untreated and kills more than 50,000 people annually, many of them children. Existing rabies vaccines target the rabies virus glycoprotein (RABV-G) but generate short-lived immune responses, likely because the protein is heterogeneous under physiological conditions. Here, we report the 3.39 Å cryo–electron microscopy structure of trimeric, prefusion RABV-G complexed with RVA122, a potently neutralizing human antibody. RVA122 binds to a quaternary epitope at the top of RABV-G, bridging domains and stabilizing RABV-G protomers in a prefusion state. RABV-G trimerization involves side-to-side interactions between the central α helix and adjacent loops, rather than contacts between central helices, and interactions among the fusion loops at the glycoprotein base. These results provide a basis from which to develop improved rabies vaccines based on RABV-G stabilized in the prefusion conformation.

29 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MNMegha Nair
Megha Nair
GGGiselle Geering
Giselle Geering
AAAlyssa Agarwal
Alyssa Agarwal
RLRebecca Li
Rebecca Li
YQYujie Qiao
Yujie Qiao
ABAmy K. Bei
Amy K. Bei
Summary: RH5-Interacting Protein (RIPR) is essential for the invasion of Plasmodium into host red blood cells and is currently being studied as a novel malaria vaccine candidate in Phase 1a clinical trials. To study the genetic diversity of RIPR, deep amplicon sequencing was used to identify RIPR mutations in Plasmodium falciparum clinical isolates (n=89) collected in Kédougou, a high malaria transmission region of Senegal. We identified nonsynonymous single nucleotide polymorphisms (SNPs) in 64/89 (71.9%) of the samples. In total, 26 non-synonymous SNPs were identified, of which 15 were novel. 16/26 SNPs were able to be threaded onto existing RIPR crystal structures to predict the effects of SNPs on RIPR stability. 7/16 mutations were predicted to destabilize RIPR while 2/16 increased the stability of RIPR. Additionally, we identified 3 SNPs (Q737K, T738K, V840L) in the EGF5-8 domains of RIPR where neutralizing antibodies are known to bind.